Summary

Germline DNA (e.g., blood, mouthwash) is the most readily accessible source of material for the identification of pharmacogenetic markers for therapy selection. However, the cancer genome is altered by many processes that could affect the expression of functional alleles in the tumor. Consequently the utility of the germline genome to predict the tumor genome is under question. Studies have suggested strong concordance between the germline and tumor genotype profiles for pharmacogenetic markers. However, genotype is only one factor involved in tumor response to chemotherapy and mechanisms such as chromosome amplification and loss, copy number variation, microsatellite instability, chromosome instability and epigenetic variation (methylation) need to be taken into account.

Key Words

Concordance chromosome amplification genotype genome germline tumor 

Notes

Acknowledgements

The author is supported by UO1 GM63340 and R21 CA113491.

References

  1. 1.
    McLeod HL, Marsh S. Pharmacogenetics goes 3D. Nat Genet2005;37:794–795.CrossRefPubMedGoogle Scholar
  2. 2.
    Kidd EA, Yu J, Li X et al. Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res2005;11:2612–2619.CrossRefPubMedGoogle Scholar
  3. 3.
    Yu J, Shannon WD, Watson MA et al. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res2005;11:2053–2062.CrossRefPubMedGoogle Scholar
  4. 4.
    Ratain MJ. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res2006;12:1658–1660.CrossRefPubMedGoogle Scholar
  5. 5.
    Hoskins JM, Mcleod HL. Cancer pharmacogenetics: the move from pharmacokinetics to pharmacodynamics. Curr Pharmacogenomics2006;4:39–46.CrossRefGoogle Scholar
  6. 6.
    Widschwendter A, Muller HM, Fiegl H et al. DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res2004;10:565–571.CrossRefPubMedGoogle Scholar
  7. 7.
    Taback B, Giuliano AE, Lai R et al. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann NY Acad Sci2006;1075:211–221.CrossRefPubMedGoogle Scholar
  8. 8.
    Meucci MA, Marsh S, Watters JW et al. CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics2005;6:59–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Feng WH, Hong G, Delecluse HJ et al. Lytic induction therapy for Epstein–Barr virus-positive B-cell lymphomas. J Virol2004;78:1893–1902.CrossRefPubMedGoogle Scholar
  10. 10.
    Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature1997; 386:623–627.CrossRefPubMedGoogle Scholar
  11. 11.
    Lenz HJ. The use and development of germline polymorphisms in clinical oncology. J Clin Oncol2004;22:2519–2521.CrossRefPubMedGoogle Scholar
  12. 12.
    Savage SA, Chanock SJ. Using germline genetic variation to investigate and treat cancer. Drug Discov Today2004;9:610–618.CrossRefPubMedGoogle Scholar
  13. 13.
    Becker I, Becker KF, Rohrl MH et al. Laser-assisted preparation of single cells from stained histological slides for gene analysis. Histochem Cell Biol1997;108:447–451.CrossRefPubMedGoogle Scholar
  14. 14.
    Tomlinson IP, Lambros MB, Roylance RR. Loss of heterozygosity analysis: practically and conceptually flawed? Genes Chromosomes Cancer2002;34:349–353.CrossRefPubMedGoogle Scholar
  15. 15.
    Pinzani P, Orlando C, Pazzagli M. Laser-assisted microdissection for real-time PCR sample preparation. Mol Aspects Med2006;27:140–159.CrossRefPubMedGoogle Scholar
  16. 16.
    Becker I, Becker KF, Rohrl MH et al. Single-cell mutation analysis of tumors from stained histologic slides. Lab Invest1996;75:801–807.PubMedGoogle Scholar
  17. 17.
    Paez JG, Janne PA, Lee JC et al. EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science2004;304:1497–1500.CrossRefPubMedGoogle Scholar
  18. 18.
    Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA2004;101:13306–13311.CrossRefPubMedGoogle Scholar
  19. 19.
    Tavares AS, Costa J, de Carvalho A et al. Tumour ploidy and prognosis in carcinomas of the bladder and prostate. Br J Cancer1966;20:438–441.CrossRefPubMedGoogle Scholar
  20. 20.
    Rooney PH, Murray GI, Stevenson DA et al. Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer1999;80:862–873.CrossRefPubMedGoogle Scholar
  21. 21.
    Rooney PH, Boonsong A, McKay JA et al. Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer2001;85:1492–1498.CrossRefPubMedGoogle Scholar
  22. 22.
    Staebler A, Karberg B, Behm J et al. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer2006;45:905–917.CrossRefPubMedGoogle Scholar
  23. 23.
    Ito C, Kumagai M, Manabe A et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood1999;93: 315–320.PubMedGoogle Scholar
  24. 24.
    Raimondi SC, Zhou Y, Mathew S et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer2003;98:2715–2722.CrossRefPubMedGoogle Scholar
  25. 25.
    Kaufman RJ, Brown PC, Schimke RT. Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci USA1979;76:5669–5673.CrossRefPubMedGoogle Scholar
  26. 26.
    Boonsong A, Marsh S, Rooney PH et al. Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet2000;121:56–60.CrossRefPubMedGoogle Scholar
  27. 27.
    McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer1996;74:508–512.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang W, Marsh S, Cassidy J et al. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res2001;61:5505–5510.PubMedGoogle Scholar
  29. 29.
    Wang TL, Diaz LA, Jr., Romans K et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA2004;101:3089–3094.CrossRefPubMedGoogle Scholar
  30. 30.
    Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst2005;97:643–655.CrossRefPubMedGoogle Scholar
  31. 31.
    Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol2002;3:137–144.CrossRefPubMedGoogle Scholar
  32. 32.
    Redon R, Ishikawa S, Fitch KR et al. Global variation in copy number in the human genome. Nature2006;444:444–454.CrossRefPubMedGoogle Scholar
  33. 33.
    Shianna KV, Willard HF. Human genomics: in search of normality. Nature2006;444:428–429.CrossRefPubMedGoogle Scholar
  34. 34.
    Jo WS, Carethers JM. Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark2006;2:51–60.PubMedGoogle Scholar
  35. 35.
    Sinicrope FA, Rego RL, Halling KC et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res2006;12:2738–2744.CrossRefPubMedGoogle Scholar
  36. 36.
    Goel A, Nagasaka T, Arnold CN et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology2007;132:127–138.CrossRefPubMedGoogle Scholar
  37. 37.
    Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle2006;5:818–823.CrossRefPubMedGoogle Scholar
  38. 38.
    Stebbing J, Bower M, Syed N et al. Epigenetics: an emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics2006;7:747–757.CrossRefPubMedGoogle Scholar
  39. 39.
    Teodoridis JM, Hall J, Marsh S et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res2005;65:8961–8967.CrossRefPubMedGoogle Scholar
  40. 40.
    Cheng Q, Cheng C, Crews KR et al. Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am J Hum Genet2006;79:264–274.CrossRefPubMedGoogle Scholar
  41. 41.
    Flanagan JM, Popendikyte V, Pozdniakovaite N et al. Intra- and interindividual epigenetic variation in human germ cells. Am J Hum Genet2006;79:67–84.CrossRefPubMedGoogle Scholar
  42. 42.
    Rae JM, Cordero KE, Scheys JO et al. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics2003;13:501–507.CrossRefPubMedGoogle Scholar
  43. 43.
    Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol2005;23:9312–9318.CrossRefPubMedGoogle Scholar
  44. 44.
    Schneider BP, Skaar TC, Sledge GW et al. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat2006;96:209–215.CrossRefPubMedGoogle Scholar
  45. 45.
    Mort R, Mo L, McEwan C et al. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer2003;89:333–337.CrossRefPubMedGoogle Scholar
  46. 46.
    Marsh S, Mallon MA, Goodfellow P et al. Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics2005;6:873–877.CrossRefPubMedGoogle Scholar
  47. 47.
    Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs2005;23:533–537.CrossRefPubMedGoogle Scholar
  48. 48.
    Kawakami K. Thymidylate synthase gene in pharmacogenetics. current Pharmacogenomics2004;2:137–147.CrossRefGoogle Scholar
  49. 49.
    Kolesar JM, Pritchard SC, Kerr KM et al. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol2002;21:1119–1124.PubMedGoogle Scholar
  50. 50.
    Cheng Q, Yang W, Raimondi SC et al. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet2005;37:878–882.CrossRefPubMedGoogle Scholar
  51. 51.
    Takahashi K, Kohno T, Matsumoto S et al. Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells. Clin Cancer Res2007;13:111–120.CrossRefPubMedGoogle Scholar
  52. 52.
    Findlay MP, Cunningham D, Morgan G et al. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer1997; 75:903–909.CrossRefPubMedGoogle Scholar
  53. 53.
    Marsh S, McKay JA, Curran S et al. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep2002;9:231–234.PubMedGoogle Scholar
  54. 54.
    Fuchs IB, Siemer I, Buhler H et al. Epidermal growth factor receptor changes during breast cancer metastasis. Anticancer Res2006;26:4397–4401.PubMedGoogle Scholar
  55. 55.
    Lorincz T, Toth J, Badalian G et al. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathol Oncol Res2006;12:149–152.CrossRefPubMedGoogle Scholar
  56. 56.
    Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer2005;103:1763–1769.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sharon Marsh
    • 1
  1. 1.Division of Molecular OncologyWashington UniversitySt. LouisUSA

Personalised recommendations